Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Merus N.V.

< Previous 1 2 Next >
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Business Update Conference Call
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Pricing of Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus N.V. Announces Proposed Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.